The company will apply its single-cell RNA-seq analytics technology to three distinct cohorts in pursuit of new drug targets for inflammatory bowel disease.
The firms are targeting a compatible offering for single-cell gene expression screens following CRISPR-based editing, with applications in drug discovery.
These hybrid capture-based methods target gene transcripts of interest, which could shrink sequencing costs for some experiments by as much as 90 percent.
Single-cell analysis, next-generation sequencing, and synthetic DNA have all been crucial to efforts to find antibodies that could neutralize SARS-CoV-2.
10x asked the US District Court for the Northern District of California to dismiss a suit, while another district court judge denied a 10x motion to dismiss.
At the Biology of Genomes virtual conference last week, several presentations focused on single-cell and spatial genomics data sets and how they could be complementary.
The Pleasanton, California-based firm reported $71.9 million in revenues but missed the consensus Wall Street estimates for quarterly revenues as well as loss per share.
Bio-Rad said it is withdrawing its previously issued annual revenue guidance given the uncertainties regarding the duration and impact of the COVID-19 pandemic.
In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.
